The integration of neural components into organoid models to dissect tumor–nerve crosstalk and screen therapies targeting neurotrophic factors (e.g., NGF, BDNF) or glutamate receptors (α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA)/N-Methyl-D-Aspartate (NMDA)) is crucial. The gene discussed is NGF; the disease is neoplasm.